|
Prevalence of iron deficiency in cancer patients: The French prospective CARENFER study. |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Pfizer |
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Merck Serono; MSD Oncology; Pfizer |
| |
|
Consulting or Advisory Role - AstraZeneca; Ipsen; Janssen; Novartis; Pfizer |
Research Funding - AstraZeneca |
Travel, Accommodations, Expenses - Astellas Oncology; AstraZeneca; Ipsen; Novartis; Pfizer |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Abbott; Boston Scientific; Novartis; Vifor Pharma |
Research Funding - Novartis |
(OPTIONAL) Uncompensated Relationships - Corvia Medical |
| |
|
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Mylan; Vifor Pharma |
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Mylan; Vifor Pharma |
Speakers' Bureau - Abbvie; AstraZeneca; Mylan; Vifor Pharma |
Research Funding - Abbvie; Bristol-Myers Squibb; Mylan |